T 0890/12 (NY-ESO-1 cancer vaccine/LUDWIG INSTITUTE) of 13.10.2016
- European Case Law Identifier
- ECLI:EP:BA:2016:T089012.20161013
- Date of decision
- 13 October 2016
- Case number
- T 0890/12
- Online on
- 1 February 2017
- Petition for review of
- -
- Application number
- 04789341.7
- IPC class
- A61K 39/00A61K 39/385
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- In vivo efficacy of NY-ESO-1 plus adjuvant
- Applicant name
- Ludwig Institute for Cancer Research
CSL Limited - Opponent name
- -
- Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 56
- Keywords
- Main request - meets requirements of EPC (yes)
- Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the examining division with the order to grant a patent with the following claims and a description to be adapted thereto:
claims 1 to 13 of the main request filed during the oral proceedings and labelled "13th October 2016".